Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Protein C or activated protein C-like molecules

A protein, active technology, applied in the field of protein C or activated protein C-like molecules, can solve the problems of short half-life, high cost, difficult dose adjustment and so on

Inactive Publication Date: 2004-10-06
PERSEID THERAPEUTICS
View PDF57 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0014] However, due to the short half-life of APCs, relatively high doses and frequent dosing are necessary to achieve and maintain the desired therapeutic or prophylactic effect
As a result, adequate dose adjustment is difficult and the need for frequent intravenous administration of high levels of APC is problematic and expensive

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Protein C or activated protein C-like molecules
  • Protein C or activated protein C-like molecules
  • Protein C or activated protein C-like molecules

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0044] definition

[0045] Throughout this application and the present invention, the following definitions are used:

[0046] The term "conjugate" (or interchangeably "conjugated polypeptide") refers to a combination of one or more polypeptides and one or more non-polypeptide components such as polymer molecules, lipophilic compounds, sugar components or organic Derivatizing agents) are covalently linked to form hybrid (referred to as composite or chimeric) molecules. Preferably, the conjugate is soluble at relevant concentrations and conditions, ie in physiological fluids such as blood. Examples of conjugated polypeptides of the invention include glycosylated polypeptides and / or PEGylated polypeptides.

[0047] The term "covalently linked" means that a polypeptide and a non-polypeptide component are covalently linked to each other directly, or indirectly through one or more intervening components, such as bridges, spacers or linking components.

[0048] The term "non-conj...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Molecular weightaaaaaaaaaa
Login to View More

Abstract

The present invention relates to novel conjugates between polypeptide variants of protein C and a non-polypeptide moiety, such as PEG or sugar moieties. In particular, the present invention provides novel protein C conjugates having an increased resistance to inactivation by e.g. human plasma and alpha1-antitrypsin. Consequently, such conjugates have an increased in vivo half-life. Preferred examples include protein C conjugates, wherein at least one additional in vivo N-glycosylation site has been introduced. The conjugates of the invention are useful for treating a variety of diseases, including septic shock.

Description

technical field [0001] The present invention relates to novel conjugates of polypeptide variants of protein C and non-polypeptide components, means and methods for preparing said conjugates, pharmaceutical compositions comprising said conjugates, and said conjugates The use of drugs in therapy, especially in the treatment of various coagulation disorders. The invention also relates to the polypeptide portion of said conjugate. Background technique [0002] Coagulation is a process consisting of complex interactions between various blood components, or factors, that gradually leads to the formation of a fibrin clot. The blood components normally involved in the coagulation "cascade" are proenzymes or zymogens, ie, proteins that are not enzymatically active and which can be converted to an active form by the action of an activator. The regulation of blood coagulation is mainly realized by the inactivation of coagulation factors Va and VIIIa by activated protein C (APC) throu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/48C07KC12N9/64C12N15/57
Inventor 金·V·安德森安德斯·H·佩德森珀·O·弗雷斯克加尔德
Owner PERSEID THERAPEUTICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com